Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7440MR)

This product GTTS-WQ7440MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7440MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15970MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ7808MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ11953MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ6375MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ10672MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ158MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ5192MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ4763MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW